Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party
(2011) In Blood 118(6). p.1693-1698- Abstract
- To specify the incidence and risk factors for secondary autoimmune diseases (ADs) after HSCT for a primary AD, we retrospectively analyzed AD patients treated by HSCT reported to EBMT from 1995 to 2009 with at least 1 secondary AD (cases) and those without (controls). After autologous HSCT, 29 of 347 patients developed at least 1 secondary AD within 21.9 (0.6-49) months and after allogeneic HSCT, 3 of 16 patients. The observed secondary ADs included: autoimmune hemolytic anemia (n = 3), acquired hemo- philia (n = 3), autoimmune thrombocytopenia (n = 3), antiphospholipid syndrome (n = 2), thyroiditis (n = 12), blocking thyroid-stimulating hormone receptor antibody (n = 1), Graves disease (n = 2), myasthenia gravis (n = 1), rheumatoid... (More)
- To specify the incidence and risk factors for secondary autoimmune diseases (ADs) after HSCT for a primary AD, we retrospectively analyzed AD patients treated by HSCT reported to EBMT from 1995 to 2009 with at least 1 secondary AD (cases) and those without (controls). After autologous HSCT, 29 of 347 patients developed at least 1 secondary AD within 21.9 (0.6-49) months and after allogeneic HSCT, 3 of 16 patients. The observed secondary ADs included: autoimmune hemolytic anemia (n = 3), acquired hemo- philia (n = 3), autoimmune thrombocytopenia (n = 3), antiphospholipid syndrome (n = 2), thyroiditis (n = 12), blocking thyroid-stimulating hormone receptor antibody (n = 1), Graves disease (n = 2), myasthenia gravis (n = 1), rheumatoid arthritis (n = 2), sarcoidosis (n = 2), vasculitis (n = 1), psoriasis (n = 1), and psoriatic arthritis (n = 1). After autologous HSCT for primary AD, the cumulative incidence of secondary AD was 9.8% +/- 2% at 5 years. Lupus erythematosus as primary AD, and antithymocyte globulin use plus CD34(+) graft selection were important risk factors for secondary AD by multivariate analysis. With a median follow-up of 6.2 (0.54-11) years after autologous HSCT, 26 of 29 patients with secondary AD were alive, 2 died during their secondary AD (antiphospholipid syndrome, hemophilia), and 1 death was HSCT-related. This European multicenter study underlines the need for careful management and follow-up for secondary AD after HSCT. (Blood. 2011;118(6):1693-1698) (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/2162154
- author
- organization
- publishing date
- 2011
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Blood
- volume
- 118
- issue
- 6
- pages
- 1693 - 1698
- publisher
- American Society of Hematology
- external identifiers
-
- wos:000293787300036
- scopus:80051637474
- pmid:21596847
- ISSN
- 1528-0020
- DOI
- 10.1182/blood-2011-02-336156
- language
- English
- LU publication?
- yes
- id
- 38beef27-fb84-4118-9270-d698d61a4b4a (old id 2162154)
- date added to LUP
- 2016-04-01 09:48:41
- date last changed
- 2025-04-04 15:13:28
@article{38beef27-fb84-4118-9270-d698d61a4b4a,
abstract = {{To specify the incidence and risk factors for secondary autoimmune diseases (ADs) after HSCT for a primary AD, we retrospectively analyzed AD patients treated by HSCT reported to EBMT from 1995 to 2009 with at least 1 secondary AD (cases) and those without (controls). After autologous HSCT, 29 of 347 patients developed at least 1 secondary AD within 21.9 (0.6-49) months and after allogeneic HSCT, 3 of 16 patients. The observed secondary ADs included: autoimmune hemolytic anemia (n = 3), acquired hemo- philia (n = 3), autoimmune thrombocytopenia (n = 3), antiphospholipid syndrome (n = 2), thyroiditis (n = 12), blocking thyroid-stimulating hormone receptor antibody (n = 1), Graves disease (n = 2), myasthenia gravis (n = 1), rheumatoid arthritis (n = 2), sarcoidosis (n = 2), vasculitis (n = 1), psoriasis (n = 1), and psoriatic arthritis (n = 1). After autologous HSCT for primary AD, the cumulative incidence of secondary AD was 9.8% +/- 2% at 5 years. Lupus erythematosus as primary AD, and antithymocyte globulin use plus CD34(+) graft selection were important risk factors for secondary AD by multivariate analysis. With a median follow-up of 6.2 (0.54-11) years after autologous HSCT, 26 of 29 patients with secondary AD were alive, 2 died during their secondary AD (antiphospholipid syndrome, hemophilia), and 1 death was HSCT-related. This European multicenter study underlines the need for careful management and follow-up for secondary AD after HSCT. (Blood. 2011;118(6):1693-1698)}},
author = {{Daikeler, Thomas and Labopin, Myriam and Di Gioia, Massimo and Abinun, Mario and Alexander, Tobias and Miniati, Irene and Gualandi, Francesca and Fassas, Athanasios and Martin, Thierry and Schwarze, Carl Philipp and Wulffraat, Nico and Buch, Maya and Sampol, Antonia and Carreras, Enric and Dubois, Benedicte and Gruhn, Bernd and Guengoer, Tayfun and Pohlreich, David and Schuerwegh, Annemie and Snarski, Emilian and Snowden, John and Veys, Paul and Fasth, Anders and Lenhoff, Stig and Messina, Chiara and Voswinkel, Jan and Badoglio, Manuela and Henes, Joerg and Launay, David and Tyndall, Alan and Gluckman, Eliane and Farge, Dominique}},
issn = {{1528-0020}},
language = {{eng}},
number = {{6}},
pages = {{1693--1698}},
publisher = {{American Society of Hematology}},
series = {{Blood}},
title = {{Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party}},
url = {{http://dx.doi.org/10.1182/blood-2011-02-336156}},
doi = {{10.1182/blood-2011-02-336156}},
volume = {{118}},
year = {{2011}},
}